357
Views
6
CrossRef citations to date
0
Altmetric
Myeloproliferative Disease

Comparison of diagnostic criteria for polycythaemia vera

, , , , &
Pages 123-130 | Published online: 04 Sep 2013

References

  • Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: Stem-cell and probable clonal origin of the disease. N Engl J Med 1976;295(17):913–916.
  • Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6 (4):372–375.
  • Wasserman LR. The treatment of polycythemia A panel discussion. Blood 1968;32(3):483–487.
  • Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12(4):339–351.
  • Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 1974;290(24):1382.
  • Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma 1996;22(Suppl 1): 87–93.
  • Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert panel on radionuclides of the international council for standardization in haematology. Br J Haematol 1995;89(4):748–756.
  • Pearson TC, Glass UN, Wetherley-Mein G. Interpretation of measured red cell mass in the diagnosis of polycythaemia. Scand J Haematol 1978;21(2):153–162.
  • Retzlaff JA, Tauxe WN, Kiely JM, Stroebel CF. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood 1969;33(5):649–661.
  • McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005;130(2):174–195.
  • Pierre R, Imbert M, Thiele J, Vardiman J, Brunning R, Flandrin G. Tumours of haematopoietic and lymphoid tissues. London: IARC Press; 2001.
  • James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144–1148.
  • Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine ldnase JAK2 in human myeloproliferative disorders. Lancet 2005;365(9464):1054–1061.
  • Levine RL, Wadleigh M, Cools J, Ebert BL, Wemig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7(4): 387–397.
  • Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Eng’ J Med 2005;352(17): 1779–1790.
  • Messinezy M, Macdonald LM, Nunan TO, Westwood NB, Chinn S, Pearson TC. Spleen sizing by ultrasound in polycythaemia and thrombocythaemia: Comparison with SPECT. Br J Haematol 1997;98(1):103–107.
  • Messinezy M, Westwood NB, Woodcock SP, Strong RNI, Pearson TC. Low serum erythropoietin—a strong diagnostic criterion of primary polycythaemia even at normal haemo-globin levels. Clin Lab Haematol 1995;17(3):217–220.
  • Cazzola M. Serum erythropoietin concentration as a diagnostic tool for polycythemia vera. Haematologica 2004;89(10):1159–1160.
  • Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004;89(10):1194–1198.
  • ICSH Recommended methods for measurement of red-cell and plasma volume: International Committee for Standard-ization in Haematology. J Nucl Med 1980;21(8):793–800.
  • Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106(6): 2162–2168.
  • Thiele JM, Kvasnicka HM. Diagnosis of polycythemia vera based on bone marrow pathology. Curr Hematol Rep 2005;4(3):218–223.
  • Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005;20(1):317–328.
  • Thiele J, Kvasnicka HM, Zankovich R, Diehl V. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 2001;86(4):368–374.
  • Johansson P, Andreasson B, Safai-Kutti S, Rhedin C, Vilen L, Vaart J, et al. On the diagnosis of polycythaemia vera as assessed in the health and medical care in the vastra gotaland region, Sweden. J Intern Med 2002;251(4):348–354.
  • Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: A study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol 2005129(5):701–705.
  • Pearson TC. Apparent polycythaemia. Blood Rev 1991;5(4):205–213.
  • Pearson TC, Guthrie DL. The interpretation of measured red cell mass and plasma volume in patients with elevated PCV values. Clin Lab Haematol 19846(3):207–217.
  • Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Huntly BJ, et al. A Polycythemia vera updated: Diagnosis pathobiology, and treatment. Hematology (Am Soc Hematol Educ Prog) 2000;51–68.
  • Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280(24):22788–22792.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.